Posted by Michael Wonder on 29 Apr 2022
Timber Pharmaceuticals announces fast track designation granted by FDA for TMB-001 in severe subtypes of congenital ichthyosis
28 April 2022 - Company expects to launch pivotal Phase 3 ASCEND clinical trial to evaluate TMB-001 within the next 60 days.
Timber Pharmaceuticals today announced that the U.S. FDA has granted fast track designation to TMB-001, a topical isotretinoin formulated using the company’s patented IPEG delivery system, for the treatment of X-linked recessive ichthyosis and autosomal recessive congenital ichthyosis lamellar ichthyosis.
